Detail

Translational Studies on Mesenchymal Stem Cells (MSC)

Our lab is now studying clinical trials using mesenchymal stem cell (MSC) that are listed in ClinicalTrials.gov, the most widely used and respected database worldwide. In the past several years we have performed an analysis of >1,000 such trial and reported in Stem Cell Translational Medicine in 2020 on a range of intravenous doses (70-190 million cells/dose) that we defined as minimal effective doses based on published data. We are currently continuing these studies with a focus on COVID-19 and found that several studies are using doses lower doses that we suggested. Additional studies are in progress for diseases of the CNS. We have also invented a system for rapid scaleup of encapsulated MSC. These are advantageous because they survive for months in vivo rather than for days by comparison to free MSC. We are searching for commercial partners producing MSC for translational studies of encapsulated MSC.